Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL over exp |
| Therapy | 20G7-D9 |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL over exp | triple-receptor negative breast cancer | sensitive | 20G7-D9 | Preclinical - Pdx | Actionable | In a preclinical study, 20G7-D9 inhibited migration and invasion of triple-negative breast cancer (TNBC) cell lines with high expression of AXL in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft models with high AXL expression levels (PMID: 27923843). | 27923843 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27923843) | Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. | Full reference... |